Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Multiple Myeloma 6 Lung Neoplasms 6 Lymphoma 5 Lymphoma, Large-Cell, Anaplastic 3 Hematologic Neoplasms 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Adenocarcinoma 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rectal Neoplasms 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibromatosis 2 1

Interventions

Bevacizumab 4 Everolimus 3 vistusertib 1 neratinib 1 icotinib 1 emvododstat 1 brigatinib 1 Vascular Endothelial Growth Factor A 1 Sunitinib 1 Sirolimus 1 Lapatinib 1 Endostatins 1 Crizotinib 1 Axitinib 1 Aspirin 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neurofibromatosis 2 × Crizotinib × Clear all

NCT04283669 2026-03-13

NF110

University of Alabama at Birmingham

Phase 2 Completed

12 enrolled 5 charts

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡